# Dr. Kim R50 Research Specialist Clinician 2022

> **NIH NIH R50** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $171,684

## Abstract

Abstract
Dr. Kim is an active and vital leader in the clinical trials program at The University of Michigan Rogel Cancer
Center whose extensive, collaborative work has supported the NCI clinical trials infrastructure institutionally
and nationally. Her key contributions to the mission and conduct of NCI-sponsored clinical trials include: 1)
Institutional leadership of the Cancer Center Neuro-Oncology clinical research group and institutional Protocol
Review Committee; 2) Serving as site Principal Investigator and central study team member for NCI-funded
clinical trials; 3) National leadership as Co-Chair of the NIH/NCI Brain Metastases Interest Group and active
member of NRG and Alliance Brain Tumor Committees; 4) National leadership in implementing practice-
changing findings from NCI-funded clinical trials as member of the NCCN Guidelines CNS Cancers Committee
and Senior Associate Editor of her specialty’s primary journal. Dr. Kim is an active investigator who has
contributed 165 patient enrollments to interventional treatment and non-treatment (supportive and
observational) trials since 2015, and has served as Principal Investigator of 5 investigator-initiated studies
which she has developed and conducted. A recently completed trial is now in development as a multi-site
study through the NRG Brain Tumor Committee. She has helped lead institutional and national efforts to
broaden trial eligibility for underrepresented demographic and disease populations. Through the support of the
Research Specialist Award, Dr. Kim proposes to advance the institutional clinical research mission, and to
establish her research and national leadership contribution to NCI funded clinical trials. To address the Cancer
Center’s objectives to increase accrual to interventional trials overall, and to increase institutional accrual of
minorities and women, Dr. Kim proposes to launch a screening program across the entire Cancer Center to
identify and enroll trial-eligible patients for CNS metastases-related trials (NCI-funded trials which have had
suboptimal accrual). To expand the catchment of a more diverse patient population from the broader oncology
community, she proposes to partner with University of Michigan affiliated community sites to develop
streamlined processes for multi-site collaboration, launch a University of Michigan Network virtual tumor board
to discuss cases and trial options, distribute newsletters and conduct CME events to increase awareness and
participation in NCI-funded and investigator-initiated trials. She will finalize and conduct as Principal
Investigator the initial phase of a developing Phase II/III Trial through NRG Oncology investigating an imaging
biomarker to personalize radiotherapy in patients with glioblastoma. She will facilitate new inter-institutional
collaborations and launch research initiatives as Co-Chair of the NIH/NCI Brain Metastases Interest Group,
and will further advance in her participation and national leadership in s...

## Key facts

- **NIH application ID:** 10806154
- **Project number:** 5R50CA276015-02
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Michelle Miran Kim
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $171,684
- **Award type:** 5
- **Project period:** 2023-03-10 → 2028-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10806154

## Citation

> US National Institutes of Health, RePORTER application 10806154, Dr. Kim R50 Research Specialist Clinician 2022 (5R50CA276015-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10806154. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*